Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Comparison of Two Urinary Catheters of Different Lengths for Female Use, in Intermittent Catheterization

26 aprile 2021 aggiornato da: Wellspect HealthCare

A Multi Centre, Single-blind, Randomized, Cross-over Study Comparing Two Female Catheters With Different Length in Terms of Residual Urine After Intermittent Catheterization

A study comparing a 10 cm catheter with a 7 cm catheter in a group of female patients who, on a routine bases, empty their bladder using urinary catheters, by measuring residual urine after intermittent catheterization.

Panoramica dello studio

Stato

Completato

Condizioni

Descrizione dettagliata

The study personnel will conduct three bladder scans after each catheterization in order to obtain the mean residual urine volume. Each patient will catheterize herself two times with each product, i.e. a total of four catheterizations.

Diagnosis and BMI will be collected at visit 1 to assess whether the residual urine volume differs between these subgroups.

The hypothesis that the mean residual volumes were equal when using the 7 and the 10 centimeter catheters was tested by means of the Wilcoxon signed rank test.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

60

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Borås, Svezia, SE-501 82
        • Rehabiliteringskliniken, Södra Älvsborgs Sjukhus
      • Gothenburg, Svezia, SE-413 45
        • Verksamhet Urologi, Sahlgrenska Universitetssjukhuset
      • Lund, Svezia, SE-221 85
        • Clinical Research and Trial Centre, Lund University Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Provision of signed informed consent
  • Female subjects aged 18 years and over
  • Experienced users of CIC with a minimum of one month of use
  • Practice CIC a minimum of 1 time per day
  • Practice CIC with female catheters with a maximum length of 20 cm
  • Perform self-catheterization
  • Sufficient hand function to be able to open and handle catheter packages
  • Use catheters with Ch 10, 12 or 14

Exclusion Criteria:

  • Pregnancy
  • Ongoing symptomatic UTI
  • Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site)
  • Previous enrolment or randomisation of treatment in the present study
  • Participation in another clinical study during the study period
  • Severe non-compliance to protocol as judged by the investigator and/or Astra Tech

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: AABB

A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 7 cm then 10 cm then 10 cm

Four catheterizations in total, two catheterizations with each study product in a randomized order.

Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Altri nomi:
  • Coloplast SpeediCath Compact 7 cm
  • Astra Tech POBE 10 cm
Sperimentale: ABAB

A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 10 cm then 7 cm then 10 cm

Four catheterizations in total, two catheterizations with each study product in a randomized order.

Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Altri nomi:
  • Coloplast SpeediCath Compact 7 cm
  • Astra Tech POBE 10 cm
Sperimentale: ABBA

A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 10 cm then 10 cm then 7 cm

Four catheterizations in total, two catheterizations with each study product in a randomized order.

Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Altri nomi:
  • Coloplast SpeediCath Compact 7 cm
  • Astra Tech POBE 10 cm
Sperimentale: BAAB

A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then 7 cm then 7 cm then 10 cm

Four catheterizations in total, two catheterizations with each study product in a randomized order.

Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Altri nomi:
  • Coloplast SpeediCath Compact 7 cm
  • Astra Tech POBE 10 cm
Sperimentale: BABA

A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then then 7 cm then 10 cm then 7 cm

Four catheterizations in total, two catheterizations with each study product in a randomized order.

Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Altri nomi:
  • Coloplast SpeediCath Compact 7 cm
  • Astra Tech POBE 10 cm
Sperimentale: BBAA

A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then 10 cm then 7 cm then 7 cm

Four catheterizations in total, two catheterizations with each study product in a randomized order.

Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Altri nomi:
  • Coloplast SpeediCath Compact 7 cm
  • Astra Tech POBE 10 cm

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Bladder Scan Measurements of Residual Urine Volume
Lasso di tempo: Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.

Measurements were performed with the bladder scan BVI 3000. The primary outcome variable was average residual urine volume (mL) calculated from repetitive bladder scans performed after each catheterization.

Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated.

Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Subjects With a Residual Volume >5mL or ≤5mL
Lasso di tempo: Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. At least 2 hours had to pass between 2 catheterizations.
Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. At least 2 hours had to pass between 2 catheterizations.
Number of Subjects With a Residual Volume >10mL or ≤10mL
Lasso di tempo: Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.
Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.
Number of Subjects With a Residual Volume >30mL or ≤30mL
Lasso di tempo: Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.
Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.
Number of Subjects With a Residual Volume >50mL or ≤50mL
Lasso di tempo: Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.
Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.
Does the Subject's Bladder Feel Completely Empty After Catheterisation (All Subjects)
Lasso di tempo: Question asked minutes after catheterization.

After each catheterization the study nurse will ask the subject whether it feels as if the bladder is completely emptied or not.

0=No and 1=Yes.

Question asked minutes after catheterization.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Ulf Malmqvist, MD, PhD, Assoc.Prof., Clinical Research and Trial Centre, Lund University Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 novembre 2008

Completamento primario (Effettivo)

1 gennaio 2009

Completamento dello studio (Effettivo)

1 marzo 2009

Date di iscrizione allo studio

Primo inviato

28 novembre 2008

Primo inviato che soddisfa i criteri di controllo qualità

28 novembre 2008

Primo Inserito (Stima)

1 dicembre 2008

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 maggio 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

26 aprile 2021

Ultimo verificato

1 aprile 2021

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • YA-LOF-0015

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su A=SpeediCath Compact 7 cm and B=POBE 10 cm

Sottoscrivi